Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Iovance Biotherapeutics (IOVA) Operating Leases (2019 - 2025)

Iovance Biotherapeutics has reported Operating Leases over the past 4 years, most recently at $44.4 million for Q4 2025.

  • Quarterly results put Operating Leases at $44.4 million for Q4 2025, changed 0.08% from a year ago — trailing twelve months through Dec 2025 was $44.4 million (changed 0.08% YoY), and the annual figure for FY2025 was $44.4 million, changed 0.08%.
  • Operating Leases for Q4 2025 was $44.4 million at Iovance Biotherapeutics, down from $45.2 million in the prior quarter.
  • Over the last five years, Operating Leases for IOVA hit a ceiling of $72.3 million in Q1 2024 and a floor of $44.2 million in Q1 2025.
  • Median Operating Leases over the past 3 years was $56.1 million (2023), compared with a mean of $56.9 million.
  • Biggest five-year swings in Operating Leases: rose 3.85% in 2024 and later crashed 38.83% in 2025.
  • Iovance Biotherapeutics' Operating Leases stood at $67.1 million in 2023, then plummeted by 33.87% to $44.4 million in 2024, then increased by 0.08% to $44.4 million in 2025.
  • The last three reported values for Operating Leases were $44.4 million (Q4 2025), $45.2 million (Q3 2025), and $45.1 million (Q2 2025) per Business Quant data.